New York, NY, United States of America

David S Rickman


Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of David S. Rickman

Introduction

David S. Rickman is a notable inventor based in New York, NY, recognized for his significant contributions to the field of cancer research. He holds three patents that focus on innovative methods for diagnosing and treating prostate cancer. His work has advanced the understanding of genetic factors associated with this disease.

Latest Patents

Rickman's latest patents include compositions and methods for diagnosing prostate cancer based on the detection of the SLC45A3-ELK4 fusion transcript. This invention describes RNA transcripts that represent a fusion of human SLC45A3 nucleic acid and human ELK4 nucleic acid, which are associated with prostate cancer. Additionally, he has developed methods for diagnosing and treating prostate cancer characterized by the NDRG1-ERG fusion. This research led to the discovery of a novel gene translocation between the NDRG1 gene and the ERG oncogene, resulting in the expression of a chimeric NDRG1-ERG protein.

Career Highlights

Throughout his career, David S. Rickman has worked with prestigious institutions such as Cornell University and the Institut National de la Santé et de la Recherche Médicale. His research has been pivotal in the field of oncology, particularly in understanding the genetic underpinnings of prostate cancer.

Collaborations

Rickman has collaborated with esteemed colleagues, including Mark A. Rubin and Dorothee Pflueger. These partnerships have further enriched his research and contributed to the advancement of cancer diagnostics and therapies.

Conclusion

David S. Rickman's innovative work in cancer research has made a significant impact on the diagnosis and treatment of prostate cancer. His patents reflect a deep understanding of genetic factors that influence this disease, showcasing his dedication to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…